Form 51-102F3
Material Change Report
Item 1Name and Address of Company
VANC Pharmaceuticals Inc. (the “Company”)
Suite 810– 789 West Pender Street
Vancouver, BC V6C 1H2
Item 2Date of Material Change
November 1, 2018
Item 3News Release
The news release was disseminated on November 1, 2018 by way of the facilities of GlobeNewswire. Copies were also filed on SEDAR with the British Columbia Securities Commission and the Alberta Securities Commission.
Item 4Summary of Material Change
The Company is pleased to announce that ithas received TSX Venture Exchange approval to change its name to Avricore Health Inc.
Item5Full Description of Material Change
5.1Full Description of Material Change
VANC Pharmaceuticals Inc. (“VANC”) isexcited to announce that further to its news release announced October 25, 2018, the Company has received TSX Venture Exchange approval to change its name (the “Name Change”) to Avricore Health Inc.
Effective at the open of the market on Monday, November 5th, 2018, VANC will be trading under its new name Avricore Health Inc. The new trading symbol will be AVCR. The CUSIP AND ISIN numbers have changed to054521109 and CA0545211090 respectively.
5.2Disclosure for Restructuring Transactions
Not applicable.
Item 6Reliance on subsection 7.1(2) or (3) of National Instrument 51-102
Not applicable.
Item 7Omitted Information
Not applicable.
Item 8Executive Officer
The following senior officer of the Company is knowledgeable about the material change and this Material Change Report and may be contacted:
Bob Rai, Chief Executive Officer and Director
Business Telephone:604-247-2639
Facsimile:604-247-2693
Item 9Date of Report
November 2, 2018